Full Record Display for the EPA National Library Catalog


OLS Field Name OLS Field Data
Main Title Support document, decision not to require testing for health effects : acrylamide /
CORP Author United States. Environmental Protection Agency. Office of Toxic Substances. Assessment Division.
Publisher U.S. Environmental Protection Agency, Office of Pesticides and Toxic Substances,
Year Published 1980
Report Number EPA 560/11-80-016
Stock Number PB80-220312
OCLC Number 08453100
Subjects Acrylamides--toxicity. ; Acrylamide--Toxicology. ; Hazardous substances.
Additional Subjects Acrylamide--Toxicology ; Hazardous substances ; Physiological effects ; Recommendations ; Assessments ; Laboratory animals ; Nervous system ; Signs and symptoms ; Testing ; Exposure ; Toxic substances ; Acrylamides ; Toxic Substances Control Act ; Public Law 94-469 ; Neurotoxins
Internet Access
Description Access URL
Library Call Number Additional Info Location Last
EJAD  EPA 560/11-80-016 Region 3 Library/Philadelphia, PA 03/20/1992
EJBD ARCHIVE EPA 560-11-80-016 Headquarters Library/Washington,DC 01/18/2011
EJED  EPA 560/11-80-016 OCSPP Chemical Library/Washington,DC 01/01/1988
ERAD  EPA 560/11-80-016 Region 9 Library/San Francisco,CA 09/04/2012
ESAD  EPA 560-11-80-016 Region 10 Library/Seattle,WA 09/10/2004
NTIS  PB80-220312 Most EPA libraries have a fiche copy filed under the call number shown. Check with individual libraries about paper copy. NTIS 01/01/1988
Collation 33 p.
Abstract It has been found that acrylamide is neurotoxic, producing central-peripheral axonopathies. The animal species in which this effect was demonstrated include rats, mice, cats, dogs, baboons, and monkeys. In addition, there are at least 48 published cases of the occupational toxicity and 5 cases of the nonoccupational toxicity of acrylamide to humans, many of whom manifested a measurable degree of neurotoxicity (central-peripheral axonopathy). In humans, the predominant signs of neurotoxicity are related to peripheral nerve involvement and, to a lesser extent, central nervous system involvement. A variety of other signs and symptoms also are generally reported, the most common ones occurring in the skin, hands, and feet. The onset of effects may be reversible, although this is not always the case. Based on laboratory data, EPA has concluded that acrylamide is a potent neurotoxicant at very low levels. This conclusion has been substantiated by a 1-year (oral administration) study in cats indicating a no-effect level of 0.3-1.0 mg/kg/day. EPA does not plan to require the health effects testing recommended by the Interagency Testing Committee. Instead, EPA plans to evaluate acrylamide for possible regulatory controls.
Notes Cover title: Assessment of testing needs : acrylamide : support document for decision not to require testing for health effects, Toxic Substances Control Act, Section 4. "EPA-560/11-80-016." "June 1980."
Place Published Washington, D.C.
Access Notes Also issued online.
Title Ser Add Ent TSCA chemical assessment series.
Alternate Title Acrylamide\ Assessment of testing needs, acrylamide
PUB Date Free Form 1980
Series Title Traced TSCA chemical assessment series
Series Title Untraced TSCA chemical assessment series
Ti Tra Differently Acrylamide Assessment of testing needs, acrylamide
NTIS Prices PC A03/MF A01
BIB Level m
Cataloging Source OCLC/T
Merged OCLC records 7364375
OCLC Time Stamp 20120830171646
Language eng
SUDOCS Number EP 5.15/2:Ac 7
Origin OCLC
OCLC Rec Leader 01935cam 2200433 a 45020